1887

Abstract

The epitope for a human papillomavirus (HPV) type 6 conformation-dependent, neutralizing monoclonal antibody (mAb) was partially mapped using HPV L1 recombinant virus-like particles (VLPs). The mAb H6.J54 is cross-reactive with the closely related HPV types 6 and 11. By making HPV-6-like amino acid substitutions in the cottontail rabbit papillomavirus (CRPV) major capsid protein L1, we were able to transfer H6.J54 binding activity into a CRPV/HPV-6 hybrid L1 protein. Full binding activity was achieved with only nine amino acid changes and identified a region centred on the HPV-6 residues 49–54. This region has previously been shown to be a critical part of HPV-6 type-specific epitopes. Fine mapping of the region by scanning a series of alanine substitution mutations showed that in HPV-6 VLPs this type-common epitope overlaps HPV-6 type-specific epitopes.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.18872-0
2003-06-01
2019-10-16
Loading full text...

Full text loading...

/deliver/fulltext/jgv/84/6/vir841493.html?itemId=/content/journal/jgv/10.1099/vir.0.18872-0&mimeType=html&fmt=ahah

References

  1. Bauer, H. M., Ting, Y., Greer, C. E., Chambers, J. C., Tashiro, C. J., Chimera, J., Reingold, A. & Manos, M. M. ( 1991; ). Genital human papillomavirus infection in female university students as determined by a PCR-based method [see comments]. JAMA 265, 472–477.[CrossRef]
    [Google Scholar]
  2. Benincasa, D., Silberklang, M., Mark, G. E., III. & Ludmerer, S. W. ( 1996; ). Rapid, high-level transient expression of papillomavirus-like particles in insect cells. Biotechniques 20, 890–895.
    [Google Scholar]
  3. Bosch, F. X., Manos, M. M., Munoz, N. & 7 other authors ( 1995; ). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group [see comments]. J Natl Cancer Inst 87, 796–802.[CrossRef]
    [Google Scholar]
  4. Breitburd, F., Kirnbauer, R., Hubbert, N. L., Nonnenmacher, B., Trin Dinh Desmarquet, C., Orth, G., Schiller, J. T. & Lowy, D. R. ( 1995; ). Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69, 3959–3963.
    [Google Scholar]
  5. Brown, D. R., Bryan, J. T., Schroeder, J. M. & 8 other authors ( 2001; ). Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 184, 1183–1186.[CrossRef]
    [Google Scholar]
  6. Bryan, J. T., Jansen, K. U., Lowe, R. S., Fife, K. H., McClowry, T., Glass, D. & Brown, D. R. ( 1997; ). Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: correlation with virus-like particle IgG concentration. J Med Virol 53, 185–188.[CrossRef]
    [Google Scholar]
  7. Chackerian, B., Lowy, D. R. & Schiller, J. T. ( 1999; ). Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles. Proc Natl Acad Sci U S A 96, 2373–2378.[CrossRef]
    [Google Scholar]
  8. Chen, X. S., Garcea, R. L., Goldberg, I., Casini, G. & Harrison, S. C. ( 2000; ). Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5, 557–567.[CrossRef]
    [Google Scholar]
  9. Christensen, N. D. & Kreider, J. W. ( 1991; ). Neutralization of CRPV infectivity by monoclonal antibodies that identify conformational epitopes on intact virions. Virus Res 21, 169–179.[CrossRef]
    [Google Scholar]
  10. Christensen, N. D., Kirnbauer, R., Schiller, J. T., Ghim, S. J., Schlegel, R., Jenson, A. B. & Kreider, J. W. ( 1994; ). Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology 205, 329–335.[CrossRef]
    [Google Scholar]
  11. Christensen, N. D., Dillner, J., Eklund, C., Carter, J. J., Wipf, G. C., Reed, C. A., Cladel, N. M. & Galloway, D. A. ( 1996a; ). Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology 223, 174–184.[CrossRef]
    [Google Scholar]
  12. Christensen, N. D., Reed, C. A., Cladel, N. M., Hall, K. & Leiserowitz, G. S. ( 1996b; ). Monoclonal antibodies to HPV-6 L1 virus-like particles identify conformational and linear neutralizing epitopes on HPV-11 in addition to type-specific epitopes on HPV-6. Virology 224, 477–486.[CrossRef]
    [Google Scholar]
  13. Christensen, N. D., Reed, C. A., Cladel, N. M., Han, R. & Kreider, J. W. ( 1996c; ). Immunization with viruslike particles induces long-term protection of rabbits against challenge with cottontail rabbit papillomavirus. J Virol 70, 960–965.
    [Google Scholar]
  14. Christensen, N. D., Cladel, N. M., Reed, C. A., Budgeon, L. R., Embers, M. E., Skulsky, D. M., McClements, W. L., Ludmerer, S. W. & Jansen, K. U. ( 2001; ). Hybrid papillomavirus L1 molecules assemble into virus-like particles that reconstitute conformational epitopes and induce neutralizing antibodies to distinct HPV types. Virology 291, 324–334.[CrossRef]
    [Google Scholar]
  15. Evans, T. G., Bonnez, W., Rose, R. C. & 8 other authors ( 2001; ). A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 183, 1485–1493.[CrossRef]
    [Google Scholar]
  16. Galloway, D. A. ( 1994; ). Human papillomavirus vaccines: a warty problem. Infect Agents Dis 3, 187–193.
    [Google Scholar]
  17. Gissmann, L., Wolnik, L., Ikenberg, H., Koldovsky, U., Schnurch, H. G. & zur Hausen, H. ( 1983; ). Human papillomavirus types 6 and 11 DNA sequences in genital and laryngeal papillomas and in some cervical cancers. Proc Natl Acad Sci U S A 80, 560–563.[CrossRef]
    [Google Scholar]
  18. Harro, C. D., Pang, Y. Y., Roden, R. B. & 10 other authors ( 2001; ). Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 93, 284–292.[CrossRef]
    [Google Scholar]
  19. Heino, P., Skyldberg, B., Lehtinen, M., Rantala, I., Hagmar, B., Kreider, J. W., Kirnbauer, R. & Dillner, J. ( 1995; ). Human papillomavirus type 16 capsids expose multiple type-restricted and type-common antigenic epitopes. J Gen Virol 76, 1141–1153.[CrossRef]
    [Google Scholar]
  20. Ho, G. Y., Bierman, R., Beardsley, L., Chang, C. J. & Burk, R. D. ( 1998; ). Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338, 423–428.[CrossRef]
    [Google Scholar]
  21. Hofmann, K. J., Cook, J. C., Joyce, J. G., Brown, D. R., Schultz, L. D., George, H. A., Rosolowsky, M., Fife, K. H. & Jansen, K. U. ( 1995; ). Sequence determination of human papillomavirus type 6a and assembly of virus-like particles in Saccharomyces cerevisiae. Virology 209, 506–518.[CrossRef]
    [Google Scholar]
  22. Jansen, K. U., Rosolowsky, M., Schultz, L. D., Markus, H. Z., Cook, J. C., Donnelly, J. J., Martinez, D., Ellis, R. W. & Shaw, A. R. ( 1995; ). Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation. Vaccine 13, 1509–1514.[CrossRef]
    [Google Scholar]
  23. Kirnbauer, R., Booy, F., Cheng, N., Lowy, D. R. & Schiller, J. T. ( 1992; ). Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic. Proc Natl Acad Sci U S A 89, 12180–12184.[CrossRef]
    [Google Scholar]
  24. Kirnbauer, R., Taub, J., Greenstone, H., Roden, R., Durst, M., Gissmann, L., Lowy, D. R. & Schiller, J. T. ( 1993; ). Efficient self-assembly of human papillomavirus type 16 L1 and L1–L2 into virus-like particles. J Virol 67, 6929–6936.
    [Google Scholar]
  25. Kirnbauer, R., Chandrachud, L. M., O'Neil, B. W. & 7 other authors ( 1996; ). Virus-like particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology 219, 37–44.[CrossRef]
    [Google Scholar]
  26. Koutsky, L. A., Ault, K. A., Wheeler, C. M., Brown, D. R., Barr, E., Alvarez, F. B., Lupinacci, L. C. & Jansen, K. U. ( 2002; ). Randomized clinical trial of human papillomavirus type 16 vaccine. New Engl J Med 347, 645–651.
    [Google Scholar]
  27. Lowe, R. S., Brown, D. R., Bryan, J. T. & 11 other authors ( 1997; ). Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 176, 1141–1145.[CrossRef]
    [Google Scholar]
  28. Ludmerer, S. W. & McClements, W. L. ( 1999; ). Humoral responses to human papillomaviruses that neutralize infectivity. Curr Top Virol 1, 169–174.
    [Google Scholar]
  29. Ludmerer, S. W., Benincasa, D. & Mark, G. E., III ( 1996; ). Two amino acid residues confer type specificity to a neutralizing, conformationally dependent epitope on human papillomavirus type 11. J Virol 70, 4791–4794.
    [Google Scholar]
  30. Ludmerer, S. W., Benincasa, D., Mark, G. E., III & Christensen, N. D. ( 1997; ). A neutralizing epitope of human papillomavirus type 11 is principally described by a continuous set of residues which overlap a distinct linear, surface-exposed epitope. J Virol 71, 3834–3839.
    [Google Scholar]
  31. Ludmerer, S. W., McClements, W. L., Wang, X. M., Ling, J. C., Jansen, K. U. & Christensen, N. D. ( 2000; ). HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology 266, 237–245.[CrossRef]
    [Google Scholar]
  32. McClements, W. L., Wang, X. M., Ling, J. C., Skulsky, D. M., Christensen, N. D., Jansen, K. U. & Ludmerer, S. W. ( 2001; ). A novel human papillomavirus type 6 neutralizing domain comprising two discrete regions of the major capsid protein L1. Virology 289, 262–268.[CrossRef]
    [Google Scholar]
  33. Moscicki, A. B., Hills, N., Shiboski, S. & 9 other authors ( 2001; ). Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 285, 2995–3002.[CrossRef]
    [Google Scholar]
  34. Munoz, N. ( 2000; ). Human papillomavirus and cancer: the epidemiological evidence. J Clin Virol 19, 1–5.[CrossRef]
    [Google Scholar]
  35. Neeper, M. P., Hofmann, K. J. & Jansen, K. U. ( 1996; ). Expression of the major capsid protein of human papillomavirus type 11 in Saccharomyces cerevisae. Gene 180, 1–6.[CrossRef]
    [Google Scholar]
  36. Pastrana, D. V., Vass, W. C., Lowy, D. R. & Schiller, J. T. ( 2001; ). NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16. Virology 279, 361–369.[CrossRef]
    [Google Scholar]
  37. Pisani, P., Parkin, D. M. & Ferlay, J. ( 1993; ). Estimates of the worldwide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 55, 891–903.[CrossRef]
    [Google Scholar]
  38. Roden, R. B., Armstrong, A., Haderer, P., Christensen, N. D., Hubbert, N. L., Lowy, D. R., Schiller, J. T. & Kirnbauer, R. ( 1997; ). Characterization of a human papillomavirus type 16 variant-dependent neutralizing epitope. J Virol 71, 6247–6252.
    [Google Scholar]
  39. Rose, R. C., Bonnez, W., Reichman, R. C. & Garcea, R. L. ( 1993; ). Expression of human papillomavirus type 11 L1 protein in insect cells: in vivo and in vitro assembly of viruslike particles. J Virol 67, 1936–1944.
    [Google Scholar]
  40. Rose, R. C., Reichman, R. C. & Bonnez, W. ( 1994; ). Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 75, 2075–2079.[CrossRef]
    [Google Scholar]
  41. Slupetzky, K., Shafti Keramat, S., Lenz, P., Brandt, S., Grassauer, A., Sara, M. & Kirnbauer, R. ( 2001; ). Chimeric papillomavirus-like particles expressing a foreign epitope on capsid surface loops. J Gen Virol 82, 2799–2804.
    [Google Scholar]
  42. Suzich, J. A., Ghim, S. J., Palmer Hill, F. J., White, W. I., Tamura, J. K., Bell, J. A., Newsome, J. A., Jenson, A. B. & Schlegel, R. ( 1995; ). Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 92, 11553–11557.[CrossRef]
    [Google Scholar]
  43. Volpers, C., Schirmacher, P., Streeck, R. E. & Sapp, M. ( 1994; ). Assembly of the major and the minor capsid protein of human papillomavirus type 33 into virus-like particles and tubular structures in insect cells. Virology 200, 504–512.[CrossRef]
    [Google Scholar]
  44. Yeager, M. D., Aste Amezaga, M., Brown, D. R. & 9 other authors ( 2000; ). Neutralization of human papillomavirus (HPV) pseudovirions: a novel and efficient approach to detect and characterize HPV neutralizing antibodies. Virology 278, 570–577.[CrossRef]
    [Google Scholar]
  45. Zhou, J., Sun, X. Y., Stenzel, D. J. & Frazer, I. H. ( 1991; ). Expression of vaccinia recombinant HPV-16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology 185, 251–257.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.18872-0
Loading
/content/journal/jgv/10.1099/vir.0.18872-0
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error